It is indeed a rewarding experience for transplant surgeons when the donor heart, after being weaned from the cardiopulmonary bypass, beats in sinus rhythm, with satisfactory haemodynamics, and has excellent biventricular function as assessed by transoesophageal echocardiography, the chest is closed and the patient returns to the intensive care unit for postoperative monitoring and recovery. Conversely, it becomes a humbling and indeed terrifying experience when, while waiting expectantly, we find that the transplanted heart does not contract, but we observe an echocardiogram showing arrhythmias, which herald impending cardiac failure [1]. When this happens, we may have a recipient who cannot be weaned from cardiopulmonary bypass despite maximal medical management, or the donor heart may begin to fail on the intensive care unit, which may end in graft failure during his/her hospital stay. Why does the transplanted heart fail? It is believed to be largely due to the mechanism of ischaemia-reperfusion injury. Graft failure may result from long ischaemic times, inadequate myocardial preservation at the time of procurement, hyperacute rejection, which is extremely rare, or poor adaptation of the graft to the recipient’s haemodynamic environment. It may also be caused by donor heart hypertrophy, coronary artery disease, air embolism and the neural influence of the donor’s brain death. In children, it may be due to increased pulmonary vascular resistance either as a consequence of left ventricular (LV) failure or as a result of single ventricle physiology, resulting in the risk of right ventricular failure after transplantation [2]. Primary graft failure is a severe cardiac dysfunction of the cardiac allograft without obvious anatomical or immunological causes [2], characterized by hypotension, high filling pressures, and refractory low-cardiac output, and mostly right ventricular failure after coming off the cardiopulmonary bypass. Measures aimed at decreasing pulmonary vascular resistance after transplantation include the use of inhaled nitric oxide as well as medications with pulmonary vasodilator effects such as prostacyclin and milrinone. Graft ventricular function is also supported postoperatively with inotropes. However, despite these interventions, ventricular failure may persist, and mechanical circulatory support (MCS) then becomes necessary. Prior to the introduction of MCS, primary graft failure was fatal except in isolated cases where emergency salvage retransplantation, sometimes after prolonged periods of extracorporeal circulation, was attempted, but the outcomes of this strategy were poor [3], and it has, therefore, been seldom applied. With the advent of MCS devices, hopes of rescuing failing transplanted hearts have been resurging. Presently, we offer support either with extracorporeal membrane oxygenation (ECMO) or with ventricular assist devices (VADs), depending on whether recovery can be expected or retransplantation is anticipated.